F. Hoffmann-La Roche Ltd (ROG) - Medical Equipment - Deals and Alliances Profile

F. Hoffmann-La Roche Ltd (ROG) - Medical Equipment - Deals and Alliances Profile


  • Products Id :- GDME756D
  • |
  • Pages: 228
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

F. Hoffmann-La Roche Ltd (Roche) is a biotechnology company, which develops drugs and diagnostics that improve the standard of care in major disease areas. It provides pharmaceuticals in cancer, neuroscience, infection, immunology, ophthalmology, cardiovascular and metabolism, hematology, neurology and respiratory disease areas. The company also provides in vitro diagnostics and tissue-based cancer diagnostics, besides diabetes management solutions. Roche conducts research to identify novel methods to prevent, diagnose and treat diseases. The company offers its products and services to hospitals, commercial diagnostic laboratories, healthcare professionals, researchers and pharmacists. Together with its subsidiaries and partners, the company has operations in various countries all over the world. Roche is headquartered in Basel, Switzerland.

F. Hoffmann-La Roche Ltd (ROG)-Medical Equipment-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 7

List of Figures 9

F. Hoffmann-La Roche Ltd, Medical Equipment, Deals By Year, 2012 to YTD 2018 11

F. Hoffmann-La Roche Ltd, Medical Equipment Deals By Type, 2012 to YTD 2018 12

F. Hoffmann-La Roche Ltd, Medical Equipment, Deals By Region, 2012 to YTD 2018 13

F. Hoffmann-La Roche Ltd, Medical Equipment, Deals By Market, 2012 to YTD 2018 14

F. Hoffmann-La Roche Ltd, Medical Equipment, Deals Summary, 2012 to YTD 2018 15

F. Hoffmann-La Roche Ltd, Medical Equipment, Deal Details 25

Asset Purchase 25

Roche Latvija to Acquire Distribution Business from Medilink 25

Roche Diagnostics to Acquire Tissue Dissection Technology from AvanSci Bio 26

Genentech Acquires NanoPrint LM60 Microarrayer Platform From Arrayit 27

Venture Financing 28

Care Innovations Raises Funds through Series B Venture Financing 28

Syapse Raises USD30 Million in Series D Financing 29

Viewics Raises Additional USD10.5 Million in Series B Venture Financing 31

Omicia Raises USD23 Million in Series B Financing Round 32

Cota Raises Funds through Venture Financing 33

Purigen Biosystems Raises USD18.2 Million in Series A Financing 34

Flatiron Health Raises USD175 Million in Series C Financing 35

mySugr Raises USD4.8 Million in Venture Financing 37

Curetis Raises USD18 Million in Extended Series B Venture Financing 38

GeneWeave Biosciences Raises USD12 Million in Series B Venture Financing 40

Flatiron Health Raises USD 130 Million In Series B Financing 41

Curetis Raises USD 16.3 Million In Series B Financing 43

MacuLogix Raises USD 3.6 Million In Series A Financing 45

Flatiron Health Raises USD 8 Million In Series A Financing 46

NexDx Raises USD 5.5 Million In Series B Financing 48

Foundation Medicine Secures USD42.5 Million In Series B Financing 49

GeneWeave Raises USD 12 Million In Series A Financing Round 51

GeneWeave Biosciences Raises USD12 Million in Venrture Financing 52

Aria Diagnostics Secures USD 52.7 Million In Series C Venture Financing 53

Ariosa Diagnostics Secures USD52.7 Million in Series C Funding Round 54

Partnerships 55

Genentech Enters into Licensing Agreement with Vital Art and Science 55

Roche Enters into Licensing Agreement with Becton Dickinson 56

Ariosa Diagnostics Enters into Licensing Agreement with Labs 57

Foundation Medicine Enters into Licensing Agreement with WuXi PharmaTech 58

Roche Enters Into Licensing Agreement With Sysmex Inostics For emPCR Patent Portfolio 59

Thermo Fisher Scientific Extends Licensing Agreement With Roche For Procalcitonin Test 60

Ventana Medical Systems Enters Into Licensing Agreement With Biocare Medical 61

Ventana Medical Enters Into Licensing Agreement With German Cancer Research Center And University Hospital Heidelberg For BRAF V600E 62

Ventana Medical Enters Into Licensing Agreement With Gen-Probe For IP Of ERG Marker 63

NexDx Enters Into Licensing Agreement With University of California For Epigenetic Biomarkers 64

Roche Enters Into Licensing Agreement With Life Technologies For PCR Technology 65

Ventana Medical Systems Enters Into Licensing Agreement With Cell Signaling Technology 66

Roche Enters into Development Agreement with Novo Nordisk 67

Roche Enters into Partnership Agreement with Care Innovations 68

Five Prime Therapeutics Enters into Partnership with Roche 69

Foundation Medicine Enters into Partnership with Merck 70

Foundation Medicine, Roche and DIAN Diagnostics Enter into Partnership 71

Emulate Enters into Agreement with Roche 72

BioPorto Enters into Distribution Agreement with Roche Diagnostics 73

Syapse Enters into Agreement with Roche 74

Roche Enters into Partnership with GE Healthcare 75

Inotrem Enters into Research Agreement with Roche Diagnostics 76

Mimetas and Roche Jointly Develops Gut-On-A-Chip Technology 77

Roche Enters into Agreement with Accenture 78

Senseonics Holdings Enters into Agreement with TypeZero and Roche Diabetes 79

Loxo Oncology Enters into Agreement with Ventana Medical Systems 80

Roche Diabetes Care Enters into Agreement with Medtronic 81

Good Start Genetics Enters into Marketing Agreement with Roche Diagnostics 82

Berkeley Lights Enters into Agreement with F. Hoffmann-La Roche 83

Roche Enters into Agreement with BARDA 84

Horizon Discovery Group Enters into Co-Development Agreement with Ventana Medical Systems 85

Foundation Medicine Enters into Agreement with AstraZeneca 86

Senseonics Amends its Distribution Agreement with F. Hoffmann-La Roche 87

Flatiron Health Partners with Amgen 88

Flatiron Health Partners with Celgene 89

Cellnovo Enters into Agreement with Roche Diagnostics 90

Blueprint Medicines Enters into Co-Development Agreement with Ventana Medical Systems 91

Foundation Medicine Enters into Agreement with Mirati Therapeutics 92

IMS Health Enters into Agreement with Foundation Medicine 93

Halozyme Therapeutics Enters into Co-Development Agreement with Ventana Medical Systems for Cancer Treatment 94

Varian Medical Systems Enters into Co-Development Agreement with Flatiron Health 95

Foundation Medicine Enters into Co-Development Agreement with Flatiron Health 96

Molecular Devices Enters into Co-Development Agreement with Roche Diagnostics 97

Ventana Medical Systems Enters into Co-Development Agreement with ImmunoGen 98

AstraZeneca Enters into Co-Development Agreement with Roche 99

Advanced Biological Labs Extends Co-Promotion Agreement with Roche Diagnostics 100

Bioprocessing Tech Institute Enters Into Agreement with Roche to Develop Cancer Therapeutics 101

Ventana Medical Systems Enters into Co-Development Agreement with Merck Serono for Companion Diagnostic Test 102

AUT University Forms Joint Venture with Roche Diagnostics 103

Ventana Medical Enters into Co-Development Agreement with MedImmune 104

Ventana Medical Systems Enters Into Co-Development Agreement With Genmab 105

Foundation Medicine Extends Co-Development Agreement With Clovis Oncology 106

Ventana Extends Co-Development Agreement With Bayer Pharma 107

Ventana Medical Systems Enters Into Co-Development Agreement With Incyte For Companion Diagnostic Tests 108

Ventana Medical Systems Enters Into Agreement With Boehringer Ingelheim For Companion Diagnostic Tests 109

Ariosa Diagnostics Enters Into Agreement With Fleury For Harmony Prenatal Test 110

Genia Technologies Enters Into Agreement With Columbia University And Harvard Medical To Develop NanoTag DNA Sequencing Technology 111

Advanced Biological Labs And Roche Diagnostics Enter Into Agreement To Promote Sequencing, Genotyping And Drug Resistance Products 112

Ascendis Pharma Enters Into Collaboration Agreement with Genentech 113

Ventana Medical Systems And TGen Enter Into Agreement To Develop Cancer Diagnostic Markers 114

Ventana Medical And Barco Enter Into Agreement For Digital Pathology Imaging Platform 115

Foundation Medicine Enters Into Co-Development Agreement With Memorial Sloan-Kettering Cancer Center 116

Foundation Medicine Enters Into Agreement With Agios Pharma To Develop Cancer Diagnostics 117

Roche Enters Into Co-Development Agreement With BioLamina For Cell Culture Systems 118

Ariosa Diagnostics Enters Into Distribution Agreement With The Doctors Laboratory For Harmony Prenatal Test 119

Epizyme, Eisai And Roche Enter Into Co-Development Agreement For Companion Diagnostic Test 120

Roche Enters Into Co-Development Agreement With Precision System Science For PCR Instrument 121

NCM USA Enters Into Co-Development Agreement With Genentech For Clinical Imaging Agents 122

Foundation Medicine Enters Into Agreement With Eisai For Genomic Profiling And Diagnostic Discovery 123

Genia Technologies Enters Into Co-Development Agreement With Columbia University And Harvard University 124

Foundation Medicine Enters Into Co-Development Agreement With Clovis Oncology 125

Foundation Medicine Extends Co-Development Agreement With Novartis 126

Hycor Biomedical Enters Into Distribution Agreement With Roche For KOVA 127

Sysmex Extends Distribution Agreement With Roche 128

Seattle Genetics And Millennium Pharma Enter Into Co-Development Agreement With Ventana Medical Systems 129

Roche Enters Into Co-Development Agreement With Technoclone 131

Ventana Medical Systems Enters Into Co-Development Agreement With Bayer Pharma 132

Ventana Medical Systems Enters Into Co-Development Agreement With Pfizer 133

Foundation Medicine Enters Into Co-Development Agreement With Sanofi For Genetic Biomarkers And Potential Diagnostics 134

AEterna Zentaris Enters Into Co-Development Agreement With Ventana Medical Systems 135

Syndax Pharma Enters Into Co-Development Agreement With Ventana Medical Systems 136

Abcam Enters into Licensing Agreement with Roche 137

Sonic Healthcare Enters into Licensing Agreement with Ariosa Diagnostics 138

Roche Enters into Licensing Agreement with Dalcor Pharma 139

Equity Offering 140

Ignyta Prices Public Offering of Shares for USD160 Million 140

Senseonics Holdings Prices Private Placement of Shares for USD41 Million 142

Foundation Medicine Raises USD250 Million in Private Placement of Shares 144

Ariosa Diagnostics Withdraws IPO 145

Foundation Medicine Withdraws Public Offering Of Shares For Up To USD 150 Million 146

Foundation Medicine Completes IPO Of Shares For USD 122 Million 147

Debt Offering 149

Roche Raises USD750 Million in Public Offering of 3.25% Bonds Due 2023 149

Roche Raises USD650 Million in Public Offering of 3.625% Bonds Due 2028 150

Roche Prices Public Offering of Bonds Due 2020 for USD600 Million 151

Roche Prices Public Offering of 0.875% Bonds Due 2025 for USD1.14 Billion 152

Roche Plans to Raise USD850 Million in Public Offering of Notes 153

Roche Plans to Raise USD500 Million in Public Offering of Bonds 154

Roche Plans to Raise USD1.3 Billion in Public Offering of Bonds Due 2021 155

Roche Plans to Raise USD1.5 Billion in Public Offering of Bonds 156

Roche Plans to Raise USD1.3 Billion in Public Offering of Bonds Due 2024 157

Roche Plans to Raise USD300 Million in Public Offering of Bonds 158

Asset Transactions 159

Roche Rumored To Sell Its Diabetes Device Unit 159

SynenTec To Acquire Cellavista Systems Business From Roche 160

Acquisition 161

Roche to Acquire Remaining Stake in Foundation Medicine for USD2.4 Billion 161

Roche Acquires Flatiron Health for USD1.9 Billion 162

Roche Acquires Ignyta for USD1.7 Billion 163

Roche Acquires mySugr for USD73.1 Million 165

Roche Acquires ForSight VISION4 from ForSight Labs 166

Roche Acquires GeneWEAVE BioSciences for USD350 Million 167

Roche Acquires CAPP Medical 168

Roche Acquires Signature Diagnostics 169

Roche Acquires Ariosa Diagnostics 170

Roche Acquires Bina Technologies 171

F. Hoffmann-La Roche Completes Acquisition of Iquum for USD450 Million 172

Roche Diagnostics Acquires Genia for up to USD350 Million 173

Flatiron Health To Acquire Altos Solutions, Electronic Medical Records Company 174

Fluidigm Completes Acquisition Of DVS Sciences For USD 207.5 Million 175

Roche Rumored to Acquire BioMarin Pharma for USD13.5 Billion 177

Roche Acquires Constitution Medical For USD 220 Million 178

Celltrion Chairman Jung Jin Seo Plans To Sell Controlling Stake In The Company 179

Roche Completes Acquisition Of Verum Diagnostica For USD 15 Million 181

F. Hoffmann-La Roche Ltd - Key Competitors 182

F. Hoffmann-La Roche Ltd - Key Employees 183

F. Hoffmann-La Roche Ltd - Locations And Subsidiaries 184

Head Office 184

Other Locations & Subsidiaries 184

Recent Developments 196

Strategy And Business Planning 196

Nov 22, 2017: Roche expands its Kaiseraugst site and opens new IT innovation centre 196

Financial Announcements 197

Jul 26, 2018: Roche reports very strong performance in the first half of 2018 197

Feb 01, 2018: Roche reports good results in 2017 200

Oct 19, 2017: Roche reports strong sales growth in the first nine months of 2017 201

Jul 27, 2017: Roche reports strong performance in the first half of 2017 205

Apr 27, 2017: Roche reports a good start in 2017 207

Feb 01, 2017: Roche reports good results in 2016 209

Corporate Communications 212

Sep 13, 2018: Roche ranked the most sustainable healthcare company in the Dow Jones Sustainability Indices for the tenth year running 212

Mar 08, 2018: Changes to the Roche Enlarged Corporate Executive Committee 213

Sep 07, 2017: Roche ranked again the most sustainable healthcare company in the Dow Jones Sustainability Indices 214

Product News 215

Sep 18, 2018: LGC announces VALIDATE hsTnT kit for easier linearity and calibration verification on Roche cobas analyzers 215

Jun 07, 2018: Roche to showcase new solutions to consolidate automated molecular testing, microbiology topics from industry experts at ASM Microbe 2018 216

Nov 16, 2017: Roche launches DISCOVERY Teal HRP chromogen detection kit to advance tissue-based cancer research 217

Oct 03, 2017: Roche launches NAVIFY Tumor Board solution to provide decision support to oncology care teams 218

Jul 31, 2017: Roche to showcase power of connected lab at AACC 2017 Clinical Lab Expo 219

May 08, 2017: Roche launches AVENIO ctDNA Analysis Kits for Oncology Research 220

Apr 12, 2017: Roche launches antibody test to aid in diagnosis of challenging prostate cancer cases 221

Other Significant Developments 222

Apr 26, 2018: Roche reports a strong start in 2018 222

Mar 02, 2018: Roche achieves two major milestones in the evolution of decision support platform 224

Feb 21, 2018: Organ-on-a-chip startup partners with Roche and Takeda 225

Jul 26, 2017: Accenture To Transform Diabetic Patient Care Using Data-driven Analytics Platform 226

May 19, 2017: med fusion Launches an EGFR Liquid Biopsy Service Based on Roche EGFR Mutation Test 227

Appendix 228

Methodology 228

About GlobalData 228

Contact Us 228

Disclaimer 228

List of Figures

F. Hoffmann-La Roche Ltd, Medical Equipment, Deals by Type, 2012 to YTD 2018 2

F. Hoffmann-La Roche Ltd, Medical Equipment, Deals By Year, 2012 to YTD 2018 2

F. Hoffmann-La Roche Ltd, Medical Equipment, Deals By Region, 2012 to YTD 2018 2

F. Hoffmann-La Roche Ltd, Medical Equipment, Deals By Market, 2012 to YTD 2018 2

F. Hoffmann-La Roche Ltd, Medical Equipment, Deals By Year, 2012 to YTD 2018 11

F. Hoffmann-La Roche Ltd, Medical Equipment, Deals by Type, 2012 to YTD 2018 12

F. Hoffmann-La Roche Ltd, Medical Equipment, Deals By Region, 2012 to YTD 2018 13

F. Hoffmann-La Roche Ltd, Medical Equipment, Deals by Market, 2012 to YTD 2018 14

List of Tables

F. Hoffmann-La Roche Ltd, Medical Equipment, Key Facts, 2017 2

F. Hoffmann-La Roche Ltd, Medical Equipment, Deals Summary, 2012 to YTD 2018 2

F. Hoffmann-La Roche Ltd, Medical Equipment, Deals By Year, 2012 to YTD 2018 11

F. Hoffmann-La Roche Ltd, Medical Equipment Deals By Type, 2012 to YTD 2018 12

F. Hoffmann-La Roche Ltd, Medical Equipment, Deals By Region, 2012 to YTD 2018 13

F. Hoffmann-La Roche Ltd, Deals By Market, 2012 to YTD 2018 14

F. Hoffmann-La Roche Ltd, Medical Equipment, Deals Summary, 2012 to YTD 2018 15

Roche Latvija to Acquire Distribution Business from Medilink 25

Roche Diagnostics to Acquire Tissue Dissection Technology from AvanSci Bio 26

Genentech Acquires NanoPrint LM60 Microarrayer Platform From Arrayit 27

Care Innovations Raises Funds through Series B Venture Financing 28

Syapse Raises USD30 Million in Series D Financing 29

Viewics Raises Additional USD10.5 Million in Series B Venture Financing 31

Omicia Raises USD23 Million in Series B Financing Round 32

Cota Raises Funds through Venture Financing 33

Purigen Biosystems Raises USD18.2 Million in Series A Financing 34

Flatiron Health Raises USD175 Million in Series C Financing 35

mySugr Raises USD4.8 Million in Venture Financing 37

Curetis Raises USD18 Million in Extended Series B Venture Financing 38

GeneWeave Biosciences Raises USD12 Million in Series B Venture Financing 40

Flatiron Health Raises USD 130 Million In Series B Financing 41

Curetis Raises USD 16.3 Million In Series B Financing 43

MacuLogix Raises USD 3.6 Million In Series A Financing 45

Flatiron Health Raises USD 8 Million In Series A Financing 46

NexDx Raises USD 5.5 Million In Series B Financing 48

Foundation Medicine Secures USD42.5 Million In Series B Financing 49

GeneWeave Raises USD 12 Million In Series A Financing Round 51

GeneWeave Biosciences Raises USD12 Million in Venrture Financing 52

Aria Diagnostics Secures USD 52.7 Million In Series C Venture Financing 53

Ariosa Diagnostics Secures USD52.7 Million in Series C Funding Round 54

Genentech Enters into Licensing Agreement with Vital Art and Science 55

Roche Enters into Licensing Agreement with Becton Dickinson 56

Ariosa Diagnostics Enters into Licensing Agreement with Labs 57

Foundation Medicine Enters into Licensing Agreement with WuXi PharmaTech 58

Roche Enters Into Licensing Agreement With Sysmex Inostics For emPCR Patent Portfolio 59

Thermo Fisher Scientific Extends Licensing Agreement With Roche For Procalcitonin Test 60

Ventana Medical Systems Enters Into Licensing Agreement With Biocare Medical 61

Ventana Medical Enters Into Licensing Agreement With German Cancer Research Center And University Hospital Heidelberg For BRAF V600E 62

Ventana Medical Enters Into Licensing Agreement With Gen-Probe For IP Of ERG Marker 63

NexDx Enters Into Licensing Agreement With University of California For Epigenetic Biomarkers 64

Roche Enters Into Licensing Agreement With Life Technologies For PCR Technology 65

Ventana Medical Systems Enters Into Licensing Agreement With Cell Signaling Technology 66

Roche Enters into Development Agreement with Novo Nordisk 67

Roche Enters into Partnership Agreement with Care Innovations 68

Five Prime Therapeutics Enters into Partnership with Roche 69

Foundation Medicine Enters into Partnership with Merck 70

Foundation Medicine, Roche and DIAN Diagnostics Enter into Partnership 71

Emulate Enters into Agreement with Roche 72

BioPorto Enters into Distribution Agreement with Roche Diagnostics 73

Syapse Enters into Agreement with Roche 74

Roche Enters into Partnership with GE Healthcare 75

Inotrem Enters into Research Agreement with Roche Diagnostics 76

Mimetas and Roche Jointly Develops Gut-On-A-Chip Technology 77

Roche Enters into Agreement with Accenture 78

Senseonics Holdings Enters into Agreement with TypeZero and Roche Diabetes 79

Loxo Oncology Enters into Agreement with Ventana Medical Systems 80

Roche Diabetes Care Enters into Agreement with Medtronic 81

Good Start Genetics Enters into Marketing Agreement with Roche Diagnostics 82

Berkeley Lights Enters into Agreement with F. Hoffmann-La Roche 83

Roche Enters into Agreement with BARDA 84

Horizon Discovery Group Enters into Co-Development Agreement with Ventana Medical Systems 85

Foundation Medicine Enters into Agreement with AstraZeneca 86

Senseonics Amends its Distribution Agreement with F. Hoffmann-La Roche 87

Flatiron Health Partners with Amgen 88

Flatiron Health Partners with Celgene 89

Cellnovo Enters into Agreement with Roche Diagnostics 90

Blueprint Medicines Enters into Co-Development Agreement with Ventana Medical Systems 91

Foundation Medicine Enters into Agreement with Mirati Therapeutics 92

IMS Health Enters into Agreement with Foundation Medicine 93

Halozyme Therapeutics Enters into Co-Development Agreement with Ventana Medical Systems for Cancer Treatment 94

Varian Medical Systems Enters into Co-Development Agreement with Flatiron Health 95

Foundation Medicine Enters into Co-Development Agreement with Flatiron Health 96

Molecular Devices Enters into Co-Development Agreement with Roche Diagnostics 97

Ventana Medical Systems Enters into Co-Development Agreement with ImmunoGen 98

AstraZeneca Enters into Co-Development Agreement with Roche 99

Advanced Biological Labs Extends Co-Promotion Agreement with Roche Diagnostics 100

Bioprocessing Tech Institute Enters Into Agreement with Roche to Develop Cancer Therapeutics 101

Ventana Medical Systems Enters into Co-Development Agreement with Merck Serono for Companion Diagnostic Test 102

AUT University Forms Joint Venture with Roche Diagnostics 103

Ventana Medical Enters into Co-Development Agreement with MedImmune 104

Ventana Medical Systems Enters Into Co-Development Agreement With Genmab 105

Foundation Medicine Extends Co-Development Agreement With Clovis Oncology 106

Ventana Extends Co-Development Agreement With Bayer Pharma 107

Ventana Medical Systems Enters Into Co-Development Agreement With Incyte For Companion Diagnostic Tests 108

Ventana Medical Systems Enters Into Agreement With Boehringer Ingelheim For Companion Diagnostic Tests 109

Ariosa Diagnostics Enters Into Agreement With Fleury For Harmony Prenatal Test 110

Genia Technologies Enters Into Agreement With Columbia University And Harvard Medical To Develop NanoTag DNA Sequencing Technology 111

Advanced Biological Labs And Roche Diagnostics Enter Into Agreement To Promote Sequencing, Genotyping And Drug Resistance Products 112

Ascendis Pharma Enters Into Collaboration Agreement with Genentech 113

Ventana Medical Systems And TGen Enter Into Agreement To Develop Cancer Diagnostic Markers 114

Ventana Medical And Barco Enter Into Agreement For Digital Pathology Imaging Platform 115

Foundation Medicine Enters Into Co-Development Agreement With Memorial Sloan-Kettering Cancer Center 116

Foundation Medicine Enters Into Agreement With Agios Pharma To Develop Cancer Diagnostics 117

Roche Enters Into Co-Development Agreement With BioLamina For Cell Culture Systems 118

Ariosa Diagnostics Enters Into Distribution Agreement With The Doctors Laboratory For Harmony Prenatal Test 119

Epizyme, Eisai And Roche Enter Into Co-Development Agreement For Companion Diagnostic Test 120

Roche Enters Into Co-Development Agreement With Precision System Science For PCR Instrument 121

NCM USA Enters Into Co-Development Agreement With Genentech For Clinical Imaging Agents 122

Foundation Medicine Enters Into Agreement With Eisai For Genomic Profiling And Diagnostic Discovery 123

Genia Technologies Enters Into Co-Development Agreement With Columbia University And Harvard University 124

Foundation Medicine Enters Into Co-Development Agreement With Clovis Oncology 125

Foundation Medicine Extends Co-Development Agreement With Novartis 126

Hycor Biomedical Enters Into Distribution Agreement With Roche For KOVA 127

Sysmex Extends Distribution Agreement With Roche 128

Seattle Genetics And Millennium Pharma Enter Into Co-Development Agreement With Ventana Medical Systems 129

Roche Enters Into Co-Development Agreement With Technoclone 131

Ventana Medical Systems Enters Into Co-Development Agreement With Bayer Pharma 132

Ventana Medical Systems Enters Into Co-Development Agreement With Pfizer 133

Foundation Medicine Enters Into Co-Development Agreement With Sanofi For Genetic Biomarkers And Potential Diagnostics 134

AEterna Zentaris Enters Into Co-Development Agreement With Ventana Medical Systems 135

Syndax Pharma Enters Into Co-Development Agreement With Ventana Medical Systems 136

Abcam Enters into Licensing Agreement with Roche 137

Sonic Healthcare Enters into Licensing Agreement with Ariosa Diagnostics 138

Roche Enters into Licensing Agreement with Dalcor Pharma 139

Ignyta Prices Public Offering of Shares for USD160 Million 140

Senseonics Holdings Prices Private Placement of Shares for USD41 Million 142

Foundation Medicine Raises USD250 Million in Private Placement of Shares 144

Ariosa Diagnostics Withdraws IPO 145

Foundation Medicine Withdraws Public Offering Of Shares For Up To USD 150 Million 146

Foundation Medicine Completes IPO Of Shares For USD 122 Million 147

Roche Raises USD750 Million in Public Offering of 3.25% Bonds Due 2023 149

Roche Raises USD650 Million in Public Offering of 3.625% Bonds Due 2028 150

Roche Prices Public Offering of Bonds Due 2020 for USD600 Million 151

Roche Prices Public Offering of 0.875% Bonds Due 2025 for USD1.14 Billion 152

Roche Plans to Raise USD850 Million in Public Offering of Notes 153

Roche Plans to Raise USD500 Million in Public Offering of Bonds 154

Roche Plans to Raise USD1.3 Billion in Public Offering of Bonds Due 2021 155

Roche Plans to Raise USD1.5 Billion in Public Offering of Bonds 156

Roche Plans to Raise USD1.3 Billion in Public Offering of Bonds Due 2024 157

Roche Plans to Raise USD300 Million in Public Offering of Bonds 158

Roche Rumored To Sell Its Diabetes Device Unit 159

SynenTec To Acquire Cellavista Systems Business From Roche 160

Roche to Acquire Remaining Stake in Foundation Medicine for USD2.4 Billion 161

Roche Acquires Flatiron Health for USD1.9 Billion 162

Roche Acquires Ignyta for USD1.7 Billion 163

Roche Acquires mySugr for USD73.1 Million 165

Roche Acquires ForSight VISION4 from ForSight Labs 166

Roche Acquires GeneWEAVE BioSciences for USD350 Million 167

Roche Acquires CAPP Medical 168

Roche Acquires Signature Diagnostics 169

Roche Acquires Ariosa Diagnostics 170

Roche Acquires Bina Technologies 171

F. Hoffmann-La Roche Completes Acquisition of Iquum for USD450 Million 172

Roche Diagnostics Acquires Genia for up to USD350 Million 173

Flatiron Health To Acquire Altos Solutions, Electronic Medical Records Company 174

Fluidigm Completes Acquisition Of DVS Sciences For USD 207.5 Million 175

Roche Rumored to Acquire BioMarin Pharma for USD13.5 Billion 177

Roche Acquires Constitution Medical For USD 220 Million 178

Celltrion Chairman Jung Jin Seo Plans To Sell Controlling Stake In The Company 179

Roche Completes Acquisition Of Verum Diagnostica For USD 15 Million 181

F. Hoffmann-La Roche Ltd, Key Competitors 182

F. Hoffmann-La Roche Ltd, Key Employees 183

F. Hoffmann-La Roche Ltd, Subsidiaries 184

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

F. Hoffmann-La Roche Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license
Single User License
USD 250 INR 17845
Site License
USD 500 INR 35690
Corporate User License
USD 750 INR 53535

NEWSLETTER BY CATEGORY




Testimonials

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com